黄醇作为减轻糖尿病认知衰退的潜在药理干预:临床前研究的证据
Anđela Horvat1, Ignacija Vlašić1, Jasminka Štefulj2,3
1Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia.
Life (Basel, Switzerland)
|December 23, 2023
概括
在许多食物中发现的黄醇,通过减少炎症和氧化应激,有望保护糖尿病相关的认知衰退. 需要进一步的人体研究来证实这些神经保护作用在糖尿病患者.
科学领域:
- 神经科学是一个神经科学.
- 代谢疾病 代谢疾病
- 营养科学 营养科学
背景情况:
- 糖尿病与认知障碍有关,包括海马缩和突触可塑性降低.
- 病理机制包括先进的糖化终产物 (AGEs),氧化应激,神经炎症 (NF-κB),脑源性神经营养因子 (BDNF) 降低和神经元信号干扰.
- 饮食干预越来越被认为可以预防糖尿病并发症.
研究的目的:
- 审查糖尿病引起的认知功能障碍的分子机制.
- 总结关于黄醇对糖尿病认知衰退的神经保护作用的临床前证据.
主要方法:
- 关于黄醇和糖尿病相关认知障碍的临床前研究的综述.
- 分析受糖尿病影响和由黄醇调节的分子通路.
主要成果:
- 黄醇在临床前模型中表现出神经保护,抗氧化,抗炎和增强记忆的特性.
- 它们调节葡萄糖,减轻氧化应激和炎症,促进神经营养因子,调节神经元信号通路.
- 黄醇显示出减轻糖尿病认知障碍的潜力.
结论:
- 黄醇显示出作为减轻糖尿病相关认知衰退的饮食干预的显著潜力.
- 临床前发现是有希望的,但进一步的临床和流行病学研究是必要的,以验证糖尿病患者的这些好处.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Pathophysiology of Diabetes
944
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
944
Diabetes: Management and Pharmacotherapy
288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K


